| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| olaparib maintenance ovarian cancer | 1.37 | 0.8 | 6203 | 80 | 35 |
| olaparib | 1.13 | 0.3 | 7245 | 96 | 8 |
| maintenance | 0.17 | 0.6 | 8777 | 83 | 11 |
| ovarian | 1.72 | 0.6 | 651 | 61 | 7 |
| cancer | 1.06 | 0.3 | 5407 | 64 | 6 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| olaparib maintenance ovarian cancer | 0.75 | 0.5 | 5354 | 79 |
| olaparib for ovarian cancer | 1.15 | 0.9 | 5184 | 59 |
| olaparib maintenance approval ovarian | 0.15 | 0.2 | 4616 | 53 |
| olaparib recurrent ovarian cancer | 1.26 | 0.9 | 1278 | 87 |
| olaparib ovarian cancer overall survival | 1.87 | 0.5 | 3727 | 98 |
| olaparib fda approval ovarian cancer | 1.92 | 0.6 | 3230 | 81 |
| olaparib for non brca ovarian cancer | 1.07 | 0.9 | 5153 | 57 |
| olaparib ovarian cancer clinical trials | 0.08 | 0.4 | 5408 | 7 |
| olaparib for breast cancer | 0.49 | 0.4 | 9970 | 82 |
| olaparib platinum-resistant ovarian cancer | 1.06 | 0.6 | 1299 | 45 |
| olaparib bevacizumab ovarian cancer | 0.78 | 0.2 | 935 | 81 |
| olaparib for metastatic breast cancer | 1.41 | 0.3 | 8942 | 30 |
| ovarian cancer pembrolizumab olaparib | 0.99 | 0.5 | 6746 | 14 |
| olaparib breast cancer approval | 1.44 | 1 | 3939 | 70 |
| olaparib breast cancer uk | 0.72 | 0.5 | 9188 | 19 |
| olaparib bevacizumab ovarian cancer nice | 0.93 | 1 | 5245 | 75 |
| olaparib for pancreatic cancer | 0.58 | 0.2 | 3072 | 53 |
| cancer research uk olaparib | 0.22 | 0.7 | 5565 | 76 |
| olaparib breast cancer indication | 1.35 | 0.6 | 9256 | 52 |
